113 results
8-K
AGRX
Agile Therapeutics Inc
25 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
4:30pm
and registration on Nasdaq.
As previously disclosed, on March 27, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department
8-K
AGRX
Agile Therapeutics Inc
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm
received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) indicating that it was not in compliance with the Rule. On June 2
8-K
sq7a9van27nguplis
6 Dec 23
Other Events
8:00am
8-K
ni07lhbegue c2
2 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-10.1
d02w ko9hzv3606vz3w5
28 Sep 23
Entry into a Material Definitive Agreement
4:50pm
8-K/A
EX-10.1
w9rlg69was
22 Aug 23
Departure of Directors or Certain Officers
8:30am
8-K
p8sm937 hbh3m
5 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
EX-10.1
uykgopbz qqmpyp9
25 May 23
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
5:25pm
424B4
10vvtqvw efg3la
24 May 23
Prospectus supplement with pricing info
4:05pm